GlassScriptPhysician profile
Serena Zhang
NPI 1992387807
$6,409.42
in general payments reported to CMS, 2019-2025
32 companies · $1,849 in 2025
The $1,849 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,430 · 2024: $3,131 · 2025: $1,849.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,385 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,384.81 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,601.21 | 2023-2025 | |
| Janssen Biotech, INC. | $733.71 | 2024-2025 | Tremfya, Stelara |
| Genzyme Corporation | $561.67 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $503.38 | 2023-2025 | Entyvio, Eohilia, Gattex |
| Ardelyx, INC. | $495.86 | 2023-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $470.68 | 2023-2025 | Xifaxan, Trulance, Relistor |
| Qol Medical, LLC | $409.30 | 2023-2025 | Sucraid, Sucraid |
| Ferring Pharmaceuticals INC. | $292.20 | 2023-2025 | Rebyota |
| Pfizer INC. | $220.89 | 2023-2025 | |
| Ironwood Pharmaceuticals, INC | $90.34 | 2024 | |
| Gilead Sciences, INC. | $87.46 | 2023-2024 | |
| Braintree Laboratories, INC. | $84.70 | 2024-2025 | Suflave, Sutab |
| Merck Sharp & Dohme LLC | $77.43 | 2023-2024 | Dificid |
| Lilly USA, LLC | $76.12 | 2025 | Omvoh |
| Janssen Scientific Affairs, LLC | $74.65 | 2024 | Stelara, Tremfya |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $65.92 | 2023 | |
| Intercept Pharmaceuticals, INC. | $65.59 | 2023 | Ocaliva |
| Daiichi Sankyo INC. | $62.90 | 2023-2024 | Injectafer |
| Phathom Pharmaceuticals, INC. | $57.88 | 2024 | Voquezna |
| Boston Scientific Corporation | $49.21 | 2023 | Spyglass, Watchman Flx |
| Medtronic, INC. | $46.65 | 2024 | Interstim, Pillcam |
| Alnylam Pharmaceuticals INC. | $40.69 | 2023 | Givlaari |
| Celltrion USA INC. | $40.39 | 2024-2025 | Zymfentra, Vegzelma |
| Ipsen Biopharmaceuticals, INC | $31.80 | 2025 | Iqirvo |
| Fresenius Kabi USA, LLC | $27.51 | 2023 | Idacio |
| Amgen INC. | $24.04 | 2023 | Amjevita |
| Madrigal Pharmaceuticals | $22.19 | 2025 | Rezdiffra |
| Enterra Medical, INC. | $20.98 | 2024 | |
| Novo Nordisk INC | $19.79 | 2023 | |
| Merit Medical Systems INC | $19.78 | 2023 | Endomaxx Stent and Delivery System |
| Sanofi Pasteur INC. | $19.56 | 2023 | |
| Celgene Corporation | $14.94 | 2023 | Zeposia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Serena Zhang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.